Rakovina Therapeutics Expands Strategic Engagement with Renowned AI Drug Discovery Pioneer Dr. Artem Cherkasov

On November 12, 2026 Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, reported an expanded strategic advisory engagement with Dr. Artem (Art) Cherkasov, PhD, an existing member of the Company’s Scientific Advisory Board (SAB).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Cherkasov, an internationally recognized pioneer in computational drug discovery, artificial intelligence and precision cancer therapeutics, will continue to serve on Rakovina’s Scientific Advisory Board while taking on a more active role as Advisor AI Drug Discovery supporting the Company’s evaluation of new AI technologies, advancement of its discovery programs and pursuit of strategic partnerships.

Dr. Cherkasov’s expanded role fits closely with Rakovina’s AI strategy, which has three elements: strengthening the Company’s relationships with leading AI drug-discovery platforms, including securing exclusivity in its DNA-damage response (DDR) field; using multiple AI platforms, each specialized for different aspects of biochemistry and drug development, rather than relying on a single tool; and considering strategic alternatives, including mergers and acquisitions, that could add technologies, programs or scale.

Rakovina has been executing this strategy. On November 10, 2026, the Company announced an exclusive, worldwide and perpetual licence for DDR oncology drug discovery to the Artemis.AI platform, which incorporates Dr. Cherkasov’s Deep Docking technology, from Artemis Therapeutics Inc. ("Artemis"), where Dr. Cherkasov is a co-founder and Chief Technology Officer. On October 14, 2026, Rakovina announced that it had secured exclusivity over the optimized target product profile for its kt-5000 ATR inhibitor program from Variational AI Inc. ("Variational AI"), and on October [22], 2026, it reported that the kt-5000AI program, designed using Variational AI’s Enki generative AI platform, is advancing toward development candidate selection. On October 1, 2026, Rakovina announced a collaboration with Boston-based Celvion Therapeutics ("Celvion") to apply Celvion’s EMphora AI platform to real-world clinical data for its ATR inhibitor program, and on October 28, 2026, the companies reported the results of their first analysis. These news releases are available on the Company’s website at www.rakovinatherapeutics.com and on SEDAR+ at www.sedarplus.ca.

"Our strategy is to build the strongest position we can in AI-enabled DDR drug discovery: exclusive access to the best platforms in our field, the flexibility to apply the right specialized AI to each problem, and openness to strategic transactions that can accelerate our growth," said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. "Art has been using AI to accelerate drug discovery for more than 20 years and has an internationally recognized track record, and few people are better placed to judge which AI technologies will deliver results in the lab. His expanded involvement will help us evaluate emerging technologies, deepen our AI partnerships and assess corporate development opportunities as we execute our growth strategy."

A World-class Scientific Leader with a Track Record of Commercial Innovation

Dr. Cherkasov is a Professor in the Department of Urologic Sciences at the University of British Columbia (UBC), a Tier 1 Canada Research Chair in Precision Cancer Drug Design and a Senior Scientist at the Vancouver Prostate Centre.

Over the course of his distinguished career, he has established an exceptional international reputation for applying computational science, machine learning and artificial intelligence to accelerate pharmaceutical discovery and therapeutic innovation.

His accomplishments include:

Pioneer of Deep Docking: Developed the groundbreaking AI-enabled drug discovery platform capable of screening billions of molecular structures against specific biological targets, dramatically accelerating the identification of potential drug candidates.

Landmark Roche / UBC Pharmaceutical Agreement: His research and computational drug discovery work contributed to a landmark licensing and commercialization agreement between UBC and Roche involving a potential treatment for advanced prostate cancer. Announced in 2015, the agreement included potential milestone payments of up to US$141.7 million, plus royalties, representing one of the most significant pharmaceutical commercialization agreements in UBC’s history.

COVID-19 AI Research Breakthrough: During the pandemic, Dr. Cherkasov led an interdisciplinary research initiative applying Deep Docking to identify potential inhibitors of SARS-CoV-2. Working with NVIDIA, Dell Technologies and UBC Advanced Research Computing, his team computationally screened approximately 40 billion molecular structures in just 19 days, identifying promising candidates for further investigation.

International AI Drug Discovery Recognition: His Deep Docking technology achieved first-place results in two international CACHE drug discovery challenges, including initiatives focused on Parkinson’s disease and COVID-19.

Extensive Intellectual Property and Research Portfolio: Dr. Cherkasov has co-authored more than 200 peer-reviewed scientific publications, contributed to more than 80 patent filings and helped advance eight drug candidates that have been licensed to pharmaceutical companies and commercial partners.

Significant Research Leadership: His work at UBC and the Vancouver Prostate Centre has attracted more than CAD $80 million in research funding, supporting advances in computational drug discovery, molecular modelling, cheminformatics and precision oncology.

Dr. Cherkasov’s career exemplifies the potential of AI to fundamentally transform traditional drug discovery by enabling researchers to explore vastly larger chemical spaces, prioritize promising compounds and accelerate the transition from computational predictions to experimental validation.

"AI and computational approaches are fundamentally changing how we discover and develop new therapeutics, creating significant opportunities to accelerate innovation," said Dr. Art Cherkasov. "Realizing this potential requires the integration of scientific expertise, advanced technologies and strategic collaboration. I am pleased to expand my involvement with Rakovina and look forward to working with the team to strengthen its discovery capabilities, explore new opportunities and help shape the Company’s next phase of growth."

The Company believes that realizing the full potential of AI-driven drug discovery requires more than computational capabilities alone. Rakovina combines expertise in AI-enabled drug design with established wet-laboratory research capabilities and deep experience in oncology drug development, enabling the Company to advance promising AI-generated compounds through experimental validation, biological testing and further preclinical development. This integrated approach positions Rakovina to translate computational discoveries into tangible therapeutic opportunities.

"Art brings exceptional expertise in computational drug discovery that complements Rakovina’s strengths in cancer biology, experimental validation and preclinical drug development," said Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. "The true potential of AI-driven drug discovery lies in our ability to translate computational predictions into compounds with demonstrated biological activity and therapeutic potential. By combining Art’s expertise with our established wet-laboratory capabilities and oncology research experience, we see significant opportunities to strengthen our discovery programs and accelerate the advancement of promising new cancer therapeutics."

Securities for Services Arrangement

In connection with his expanded role, the Company has entered into a consulting agreement with Dr. Cherkasov effective November 15, 2026, for a term of up to 24 months (the "Consulting Agreement"). Under the Consulting Agreement, Dr. Cherkasov will continue to serve on the Company’s Scientific Advisory Board and will provide advice on AI-enabled drug discovery and development and scientific and technical due diligence on new AI platforms. The services do not include investor relations, promotional or market-making activities.

Dr. Cherkasov will receive compensation of $160,000 per year, of which $100,000 is payable in cash in equal monthly instalments and $60,000 ($15,000 per quarter) is payable in common shares of the Company ("Shares") under a securities-for-services arrangement in accordance with section 6.2 of TSX Venture Exchange ("TSXV") Policy 4.4 – Security Based Compensation.

Shares will be issued quarterly in arrears, only after the services for the applicable quarter have been provided. The number of Shares for each quarter will be determined after the end of that quarter by dividing $20,000 by a deemed price per Share that will not be less than the Discounted Market Price (as defined in TSXV policies) on the date of determination. No warrants will be issued under the arrangement.

Dr. Cherkasov is Non-Arm’s Length Party of the Company. He is a co-founder, director and Chief Technology Officer of Artemis Therapeutics Inc., which is expected to receive Shares as consideration for the Artemis.AI licence announced on November 10, 2026. The arrangement will not result in the creation of a new Control Person. The issuance of Shares is subject to TSXV acceptance, and the Shares will be subject to a hold period of four months and one day from the date of issuance under applicable securities laws. The Company will issue a news release each quarter disclosing the number of Shares issued under the arrangement.

Joint Webinar

Rakovina Therapeutics will host a joint webinar with Artemis Therapeutics on November 18th at 11:30AM PCT (Vancouver time) to discuss the recently announced collaboration between the two companies. The webinar will feature Mr. Kim Oishi CEO of Rakovina, Mr. Frank Holler, CEO of Artemis and Dr. Artem Cherkasov, Co-Founder and CTO of Artemis.

(Press release, Rakovina Therapeutics, NOV 12, 2026, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-expands-strategic-engagement-with-renowned-ai-drug-discovery-pioneer-dr-artem-cherkasov [SID1234674683])

Takeda to Highlight Patient-Centered Research in Hematologic Cancers and Blood Disorders at the 68th American Society of Hematology (ASH) Annual Meeting

On November 12, 2026 Takeda (TSE:4502/NYSE:TAK) reported it will present research across a range of hematologic cancers and blood disorders at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, taking place December 12–15, 2026, in New Orleans, Louisiana. Data from more than 20 presentations will expand the body of evidence supporting Takeda’s approved and investigational medicines.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our data at ASH (Free ASH Whitepaper) this year, including new analyses showing how MIMRYLO reduced symptom and treatment burden in polycythemia vera in clinical studies, focus on supporting a more patient-centered treatment experience," said Awny Farajallah, MD, FACP, Chief Medical Officer at Takeda. "These findings, alongside early insights on our investigational medicines elritercept and mezagitamab, reflect Takeda’s commitment to advancing science and evidence generation across hematologic cancers and blood disorders."

New Evidence in Hematologic Cancers Prioritizes Patient Experience Alongside Outcomes
Key presentations in oncology will feature new analyses of MIMRYLO (rusfertide), a first-in-class hepcidin mimetic approved by the U.S. Food and Drug Administration for the treatment of erythrocytosis in adults with polycythemia vera (PV). The data being presented at ASH (Free ASH Whitepaper) include an analysis demonstrating improvement in patient-reported symptoms and post hoc analyses of efficacy and safety outcomes across key patient subgroups. Real-world evidence on the burden of phlebotomy in PV, underscoring the need for alternative therapies, will also be presented.

Additionally, an oral presentation will feature data from the ongoing Phase 2 open-label ascending dose study (NCT04419649) evaluating elritercept (TAK-226), an investigational therapy being studied for anemia associated with myelodysplastic syndrome (MDS) and myelofibrosis (MF). This analysis includes broad lower-risk MDS patient populations, including patients with ring sideroblast (RS)-negative disease and high transfusion burden. These data highlight the potential for elritercept to deliver durable responses and improve quality of life outcomes.

New Findings on Platelet Counts and PROs in a Rare, Immune-mediated Bleeding Disorder
Results from a post hoc analysis of Phase 2 data will highlight an association between platelet counts (≥100,000/µL) and beneficial patient-reported outcomes (PROs) in people living with persistent/chronic primary ITP. ITP is a rare immune-mediated bleeding disorder that causes low platelet counts and an increased risk of bleeding, which can have a debilitating impact on patients. The data are from a multicenter, randomized, double-blind study (NCT04278924) of mezagitamab, an investigational anti-CD38 monoclonal antibody. In the study, PROs were measured using the ITP Patient Assessment Questionnaire (ITP-PAQ), a validated disease-specific instrument to assess symptoms, function and health-related quality of life. Observations from the post hoc analysis indicate that platelet counts ≥100,000/μl were associated with higher scores on ITP-PAQ across multiple domains compared to platelets <30,000/μl, suggesting an association between higher platelet counts and better health-related quality of life.

Elritercept and mezagitamab are investigational medicines that have not been approved by any health authority.

Additional presentations will provide updated evidence for Takeda’s portfolio of approved treatments in lymphoma, leukemia and blood disorders.

MIMRYLO (rusfertide) IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
New or Worsening Thrombocytosis: MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.
Injection-Site Reactions: Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.
Embryo-Fetal Toxicity: Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.
ADVERSE REACTIONS
The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

USE IN SPECIFIC POPULATIONS
Lactation: Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.
Females and Males of Reproductive Potential
Pregnancy Testing: Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
Contraception: Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.
To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see MIMRYLO (rusfertide) full Prescribing Information.

About MIMRYLO (rusfertide)
MIMRYLO is a first-in-class subcutaneous treatment that mimics the action of hepcidin, a natural hormone that regulates iron homeostasis and erythrocytosis. By targeting the underlying mechanism of iron dysregulation in polycythemia vera, MIMRYLO aims to reduce excess red blood cell production and help patients maintain hematocrit control. MIMRYLO is administered once weekly via subcutaneous injection. Protagonist discovered MIMRYLO and led its development through Phase 3. Takeda has exclusive global development and commercialization rights for MIMRYLO.

About Elritercept
Elritercept is a novel investigational TGF-β ligand trap designed to restore effective hematopoiesis by addressing dysregulated activin signaling. Elritercept is currently being evaluated in three ongoing Phase 3 clinical trials: RENEW and ELRiSE MDS in patients with anemia associated with myelodysplastic syndromes (MDS), and ELRiSE MF in patients with anemia associated with myelofibrosis (MF). The U.S. Food and Drug Administration has granted Fast Track designation for the development of elritercept for very low-, low- and intermediate-risk MDS. Takeda holds rights to develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau through an exclusive licensing agreement with Keros Therapeutics.

About Mezagitamab
Mezagitamab is an investigational, fully human anti-CD38 IgG1 monoclonal antibody that depletes cells with high CD38 expression, including plasma cells, plasmablasts and natural killer cells. In ITP, targeting these antibody-producing cells has the potential to reduce pathogenic autoantibody production, which may support improvements in platelet response and platelet counts to clinically meaningful levels. The safety and efficacy of mezagitamab is currently under investigation in a pivotal Phase 3 clinical trial. The U.S. Food and Drug Administration has granted mezagitamab Orphan Drug Designation for the treatment of ITP, Fast Track Designation for chronic/persistent ITP and Breakthrough Designation for the treatment of adult patients with chronic ITP who have had an insufficient response to previous treatment.

(Press release, Takeda, NOV 12, 2026, View Source;utm_term=&utm_content=1033477&utm_id=9b2de23c-1b8d-432e-89da-925d65f93d07&sfmc_activityid=01bf63e4-57d1-4bca-96c8-9dad86fbb8f4&utm_medium=email&utm_campaign=PressReleases_EN_Automated_Gray_700px_Email1&sfmc_journey_id=9b2de23c-1b8d-432e-89da-925d65f93d07&sfmc_journey_name=rPse_seRelsa_eNEL_naJ_uonrye2_20_4rPdo&sfmc_activity_id=01bf63e4-57d1-4bca-96c8-9dad86fbb8f4&sfmc_activity_name=rPseRsleaees_sNEA_tumotadeG_ar_y07p0_xmEia1l&sfmc_asset_id=1033477&sfmc_channel=email [SID1234674702])

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

On November 12, 2026 Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, reported financial results for the third quarter ended September 30, 2026, and provided a business update, including 18-month results from the NDV-01 Phase 2 study, the registrational Phase 3 SPECTRUM program, and continued progress toward the planned year-end 2026 Investigational New Drug (IND) submission for NDV-01 and sepranolone.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program," said Sergio Traversa, Chief Executive Officer of Relmada Therapeutics.

"Initial 18-month results from the ongoing NDV-01 Phase 2 study demonstrate extended durability of complete response and continued favorable tolerability," added Bipin Dalmia, Chief Business Officer of Relmada Therapeutics. "Our Phase 3 program remains unchanged, with two independent registrational pathways in NMIBC, and we have renamed it SPECTRUM to reflect the potential breadth of NDV-01 across the NMIBC disease spectrum. We expect to begin the SPECTRUM program upon IND clearance."

CMC and Manufacturing Update

NDV-01: NDV-01 CMC program is on track for IND submission by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through completion of the Phase 3 SPECTRUM program.

Sepranolone: The Company is finalizing the stability testing of the pre-filled syringe (PFS) delivery system to enable sepranolone IND submission, which is on track for year-end 2026. We expect to start the Phase 2b trial in Prader-Willi Syndrome upon IND clearance.

NDV-01 Clinical Update

Phase 2 Study: Initial 18-month results from the ongoing Phase 2 TRGC-011 study of NDV-01 in high-risk NMIBC continue to support extended durability of NDV-01 complete responses and continued favorable tolerability profile.

Initial 18-month durability results: 23 patients in complete response (CR) at 12 months continued into the long-term extension (LTE). 86% (12/14) of evaluable patients who reached 18 months remained in CR. In the BCG-unresponsive subgroup, 11 patients continued into the LTE, and 88% (7/8) of evaluable patients who reached 18 months remained in CR. Two BCG-naïve patients (T1 at study entry) progressed to muscle-invasive disease (T2a) at the Month 15 assessment.
Updated 12-month efficacy results: Among 51 evaluable patients, the anytime CR rate was 94% (48/51) and the 12-month CR rate was 77% (24/31). In the BCG-unresponsive subgroup, the anytime CR rate was 96% (22/23) and 12-month CR rate was 73% (11/15). Through 12-months, both progression-free and cystectomy-free survival was 100%.
Safety and tolerability: To date, there were no Grade ≥3 treatment-related adverse events (TRAEs), no treatment-related serious adverse events, and no treatment-related discontinuations.

Phase 3 SPECTRUM Program: The NDV-01 Phase 3 program remains unchanged and is designed to pursue two independent registrational pathways in NMIBC:

A single-arm study in second-line (2L) high-risk BCG-unresponsive carcinoma in situ (CIS) ± Ta/T1 (Cohort 2UC), together with a separate single-arm 2L high-risk BCG-unresponsive Ta/T1 w/o CIS exploratory cohort (Cohort 2UP).
A randomized study evaluating NDV-01 as adjuvant therapy following transurethral resection of bladder tumor (TURBT) versus observation in low-grade intermediate-risk NMIBC (Cohort IRA).

The Company has changed the name of its Phase 3 program from RESCUE to SPECTRUM to better reflect the potential breadth of NDV-01 across the entire NMIBC disease spectrum. Clinical trial sites are engaged and preparing to initiate patient enrollment upon IND clearance.

Anticipated Upcoming Milestones

NDV-01:

NDV-01 United States IND submission – By year-end 2026
NDV-01 Phase 3 SPECTRUM program initiation – Upon IND clearance

Sepranolone:

Sepranolone United States IND submission – By year-end 2026
Sepranolone Phase 2b initiation in Prader-Willi Syndrome – Upon IND clearance

Financial Results

Third Quarter 2026 Financial Results

Research and development expense for the three months ended September 30, 2026, totaled $9.2 million, compared to $4.0 million for the three months ended September 30, 2025, an increase of $5.2 million. The increase was primarily attributable to higher NDV-01 and sepranolone study preparation costs, increased manufacturing and drug storage costs and higher employee compensation, partially offset by lower stock-based compensation.
General and administrative expense for the three months ended September 30, 2026, totaled $3.9 million compared to $6.3 million for the three months ended September 30, 2025, a decrease of approximately $2.4 million. The decrease was primarily driven by lower stock-based compensation and lower stock appreciation rights expense, partially offset by higher employee compensation and consulting services.
Net cash used in operating activities for the three months ended September 30, 2026, totaled $12.6 million compared to $6.7 million for the three months ended September 30, 2025.
The net loss for the three months ended September 30, 2026, was $13.9 million, or $0.12 per basic and diluted share, compared with a net loss of $10.1 million, or $0.30 per basic and diluted share, for the three months ended September 30, 2025.
As of September 30, 2026, the Company’s cash, cash equivalents, and short-term investments totaled $202.1 million, compared to cash, cash equivalents, and short-term investments of approximately $93.0 million at December 31, 2025.
The Company’s current cash, cash equivalents, and short-term investments as of September 30, 2026, are expected to provide sufficient resources to fund Company operations through 2029, including completion of the two registrational cohorts of the NDV-01 Phase 3 SPECTRUM program.
The Company had 106,694,846 shares outstanding, as of November 10, 2026.

Nine Months Ended September 30, 2026 Financial Results

Research and development expense for the nine months ended September 30, 2026, totaled $25.7 million, compared to $18.8 million for the nine months ended September 30, 2025, an increase of $6.9 million. The increase was primarily attributable to increased manufacturing and drug storage costs, higher employee compensation and higher stock appreciation rights expense, partially offset by lower study costs and lower stock-based compensation.
General and administrative expense for the nine months ended September 30, 2026, totaled $21.9 million compared to $20.0 million for the nine months ended September 30, 2025, an increase of approximately $1.9 million. The increase was primarily driven by higher employee compensation, stock appreciation rights expense and consulting services, partially offset by lower stock-based compensation.
Net cash used in operating activities for the nine months ended September 30, 2026, totaled $37.3 million compared to $31.2 million for the nine months ended September 30, 2025.
The net loss for the nine months ended September 30, 2026, was $45.8 million, or $0.44 per basic and diluted share, compared with a net loss of $37.5 million, or $1.16 per basic and diluted share, for the nine months ended September 30, 2025.

Conference Call and Webcast Information

Relmada will host a conference call and webcast today at 4:30 PM ET to discuss recent business progress and financial results.

Date: Thursday, November 12, 2026 at 4:30 PM ET
Participant Dial-in (US): 1-800-717-1738
Participant Dial-in (International): 1-646-307-1865
Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at View Source

About NDV-01

NDV-01 is a novel, sustained-release, intravesical co-formulation of gemcitabine and docetaxel (Gem/Doce) being developed for the treatment of non-muscle invasive bladder cancer (NMIBC). The formulation is engineered to provide prolonged bladder retention and sustained drug release for up to 10 days. By forming a soft intravesical matrix, NDV-01 is designed to increase local drug exposure while limiting systemic toxicity. The treatment can be administered conveniently in an office setting in under 5 minutes without the need for anesthesia or specialized equipment. NDV-01 is encompassed by multiple patent applications that if issued, could provide protection until 2047.

About the NDV-01 Phase 3 SPECTRUM Registrational Pathways:

Relmada has received written FDA feedback confirming alignment on two registrational pathways for NDV-01, including study design, patient populations, and primary endpoints. The Company expects to submit an IND by year-end 2026 and initiate the Phase 3 SPECTRUM program upon IND clearance.

About NMIBC

NMIBC represents 75-80% of all bladder cancer cases and is associated with high recurrence rates (50–80% over 5 years) and disease progression in a subset of these patients. With 63,000 incident NMIBC cases per year in the U.S. and limited treatment options, the market opportunity is significant. High-risk BCG-unresponsive disease represents the biggest unmet need in NMIBC, with limited and suboptimal bladder-sparing treatment options. While four therapies are FDA-approved for first line BCG-unresponsive disease, there are no approved therapies in the second line or later. Intermediate-risk NMIBC in the adjuvant setting has no currently approved therapies and patients with recurrence must undergo repeated surgical resections. NDV-01 has the potential to serve as a foundational intravesical therapy across the NMIBC disease spectrum.

About Sepranolone and GABA Modulation

Sepranolone, a synthetic isoallopregnanolone, selectively modulates GABAA receptors by antagonizing allopregnanolone (ALLO), without disrupting GABA signaling. It targets disorders linked to excess GABAergic activity such as Prader-Willi syndrome (PWS), Tourette syndrome, and obsessive-compulsive disorder (OCD). More than 335 patients have been treated with sepranolone in clinical trials to date, with a favorable safety profile. The Company is on track to submit the sepranolone IND by year-end 2026 and expects to initiate the Phase 2 study in Prader-Willi syndrome upon IND clearance.

About Prader-Willi Syndrome (PWS)

PWS is a rare genetic disorder caused by chromosomal deletions on chromosome 15, leading to neurodevelopmental and behavioral complications. Global prevalence is estimated to be 350,000-400,000 patients. Current treatments address symptoms but do not modify the underlying neurobehavioral pathology.

(Press release, Relmada Therapeutics, NOV 12, 2026, View Source [SID1234674719])

Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

On November 12, 2026 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, reported financial results for the third quarter ended September 30, 2026, and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms," said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. "Building on the strength of these data, we are actively preparing for our upcoming registrational trial. There are currently no treatment options specifically approved for patients with pan RAS-mutated mCRC in the first-line setting and we believe onvansertib has the potential to become an important new treatment for these patients."

Clinical Highlights

Randomized Phase 2 Trial in First-Line RAS-Mutated Metastatic Colorectal Cancer ("mCRC") Ongoing

Cardiff’s randomized Phase 2 trial evaluating onvansertib in combination with FOLFIRI/ bevacizumab ("bev") or FOLFOX/bev as first-line therapy in patients with RAS-mutated mCRC remains ongoing. Median progression-free survival ("PFS") has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm, the Company’s proposed Phase 3 regimen.

As of September 28, 2026, 6 patients remain on the FOLFIRI/bev regimen, with 5 patients in the onvansertib (20 or 30 mg) + FOLFIRI/bev arms and 1 patient on standard-of-care ("SoC") FOLFIRI/bev. Patients who remain in the 30 mg onvansertib + FOLFIRI/bev arm have been on treatment for at least 21 months, with the longest duration of treatment being over 29 months.

For comparison, the median PFS in the combined SoC arms has been reached at approximately 11 months, consistent with what has been historically reported.

Corporate Updates

·
In July, Cardiff completed a $10 million registered direct offering of common stock and warrants to support working capital and general corporate purposes. The full press release is available here.
·
In September, Cardiff and its licensor, Nerviano Medical Sciences S.r.l. ("NMS"), resolved all outstanding disputes regarding global rights to onvansertib and amended their 2017 exclusive license agreement. The full press release is available here.
·
In October, Cardiff appointed Leila Alland, MD, as interim Chief Medical Officer. Dr. Alland is a seasoned oncology executive who has served as Chief Medical Officer at several clinical-stage biotechnology companies and previously held leadership positions at AstraZeneca, Bristol Myers Squibb, Novartis and Schering-Plough, where she contributed to the development and approval of multiple oncology therapies. The full press release is available here.

Upcoming Events

·
Cardiff management will present at the UBS Global Biopharma Conference and participate in one-on-one investor meetings on November 16–17, 2026. Dr. Mohindru’s presentation is scheduled for November 16 at 2:40 p.m. GMT. A live webcast and replay will be available in the "Events" section of the Cardiff Oncology website.
·
Updated data from an investigator-sponsored clinical trial in CMML will be presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) ("ASH") Annual Meeting on December 13, 2026.

Third Quarter 2026 Financial Results

Liquidity, cash burn, and cash runway

As of September 30, 2026, Cardiff Oncology had approximately $33.8 million in cash, cash equivalents, and short-term investments. Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $33.9 million, an increase of $2.0 million from $31.9 million for the same period in 2025. In July 2026, the Company raised net proceeds of approximately $9.1 million in a registered direct offering. Based on its current expectations and projections, the Company believes its current cash resources are sufficient to fund its operations to the end of the third quarter of 2027.

Operating results

Total operating expenses were approximately $32.0 million for the nine months ended September 30, 2026, a decrease of $9.5 million from $41.5 million for the same period in 2025. R&D expenses decreased by $12.5 million, reflecting the completion of clinical trials, fewer patients on treatment in the Phase 2 mCRC trial, a reduction in preclinical activities, and completion of chemistry, manufacturing and controls ("CMC") activities as the Company prepares for its planned Phase 3 mCRC trial. SG&A expenses increased by $3.1 million, driven by legal and professional fees related to the Company’s dispute with NMS, which was resolved on September 14, 2026, and also by employee severance costs. Net loss was $30.4 million, compared with $38.6 million for the prior year period.

(Press release, Cardiff Oncology, NOV 12, 2026, View Source [SID1234674668])

NuCana Reports Third Quarter 2026 Financial Results and Provides Business Update

On November 12, 2026 NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company") reported financial results for the third quarter ended September 30, 2026 and provided an update on the development of its two lead anti-cancer product candidates, NUC-7738 and NUC-3373.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"NuCana’s priorities are to define the next stage of clinical development for NUC-7738 in melanoma following the anticipated December announcement of the Phase 2 NuTide:701 expansion study results and latest translational data," said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. "Recruitment is complete in our Phase 2 expansion cohort of NuTide:701, evaluating NUC-7738 in combination with Keytruda (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma. We plan to present these results and the latest translational data at the ESMO (Free ESMO Whitepaper) Immuno-Oncology & Advanced Therapies Congress 2026, taking place December 14-16 in London. Following clearance of our Investigational New Drug application ("IND") earlier this year, we are continuing our dialogue with the U.S. Food and Drug Administration (the "FDA") regarding a potential registrational strategy for NUC-7738 in melanoma. The grant of a European composition-of-matter patent for NUC-7738 further strengthens our intellectual property position, building on similar patents in the United States and China."

Mr. Griffith continued, "We believe we have established a clear development pathway for NUC-3373 through an extensive AI-enabled analysis of proprietary data from more than 800 cancer cell lines alongside large public datasets. We believe this work has further characterized NUC-3373’s mechanism of action and differentiation from 5-fluorouracil (5-FU), supporting its greater anti-cancer activity in preclinical models compared with 5-FU and enabling us to prioritize tumor types, identify potential biomarkers of sensitivity and select rational combination strategies for further evaluation. The next phase of testing is now under way in cancer cell lines and our in-house patient-derived organoid models, which is intended to validate these findings and help guide the selection of potential future clinical development opportunities. This work gives us a focused basis for advancing NUC-3373 in settings where its differentiated biology may offer the greatest potential to benefit patients."

Mr. Griffith concluded, "With cash resources anticipated to fund our planned operations into 2029, we are focused on delivering the NUC-7738 Phase 2 expansion results, defining its potential registrational strategy and advancing the preclinical validation of NUC-3373. We are excited by the opportunities ahead and look forward to updating shareholders on these priorities."

2026 Anticipated Milestones

NUC-7738

Announce final data from the Phase 2 expansion study (NuTide:701) of NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant melanoma;
Obtain regulatory guidance from the FDA regarding a potential registrational strategy for NUC-7738 in melanoma; and
Advance evaluation of additional indications and combination strategies.

NUC-3373

Complete evaluation of optimal combinations and indications to inform potential future clinical studies of NUC-3373.

Third Quarter 2026 Financial Highlights and Cash Position

As at September 30, 2026, NuCana had cash and cash equivalents of £18.3 million compared to £19.5 million at June 30, 2026 and £24.3 million at December 31, 2025. NuCana anticipates its cash and cash equivalents at September 30, 2026 will be sufficient to fund its planned operations into 2029.

NuCana reported a net loss of £1.6 million for the quarter ended September 30, 2026, as compared to a net loss of £0.3 million for the quarter ended September 30, 2025. Basic and diluted loss per ordinary share was £0.00 for the quarter ended September 30, 2026, as compared to a loss per ordinary share of £0.00 for the comparable quarter ended September 30, 2025.

NuCana reported a net loss of £8.6 million for the nine months ended September 30, 2026, as compared to a net loss of £26.9 million for the nine months ended September 30, 2025. The net loss for the nine months ended September 30, 2026 and for the comparable period included the following non-cash or non-recurring items:

Share-based payment expenses of £3.3 million (2025: £9.1 million);
Professional fees of £nil (2025: £1.4 million) relating to the issue of warrants; and
Finance expense of £nil (2025: £12.6 million) relating to the non-cash loss on fair value revaluation of the warrants issued in the May 2025 financing; partly offset by
Total other income of £nil (2025: £2.7 million).

Basic and diluted loss per ordinary share was £0.00 for the nine months ended September 30, 2026, as compared to a loss per ordinary share of £0.00 for the comparable nine months ended September 30, 2025.

(Press release, Nucana, NOV 12, 2026, View Source [SID1234674703])